Design Therapeutics Inc [DSGN] stock prices are up 6.55% to $6.02 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DSGN shares have gain 28.91% over the last week, with a monthly amount glided 6.74%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Design Therapeutics Inc [NASDAQ: DSGN] stock has seen the most recent analyst activity on May 07, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $12 from $6. Previously, Piper Sandler downgraded its rating to Neutral on November 14, 2023, and dropped its price target to $6. On August 15, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $6 on the stock. SVB Securities downgraded its rating to a Market Perform but stick to its price target of $6 on August 15, 2023. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $7 on August 15, 2023. Goldman upgraded its rating to Neutral for this stock on May 04, 2023, but kept the price target unchanged to $6. In a note dated June 10, 2022, Wedbush initiated an Outperform rating and provided a target price of $21 on this stock.
The stock price of Design Therapeutics Inc [DSGN] has been fluctuating between $1.96 and $6.91 over the past year. Currently, Wall Street analysts expect the stock to reach $9.67 within the next 12 months. Design Therapeutics Inc [NASDAQ: DSGN] shares were valued at $6.02 at the most recent close of the market. An investor can expect a potential return of 60.63% based on the average DSGN price forecast.
Analyzing the DSGN fundamentals
Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -75.64%, Pretax Profit Margin comes in at -60.3%, and Net Profit Margin reading is -60.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.18 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.75 points at the first support level, and at 5.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.16, and for the 2nd resistance point, it is at 6.29.
Ratios To Look Out For
It’s worth pointing out that Design Therapeutics Inc [NASDAQ:DSGN]’s Current Ratio is 41.42. Also, the Quick Ratio is 41.42, while the Cash Ratio stands at 7.15.
Transactions by insiders
Recent insider trading involved William Arsani, Director, that happened on Aug 09 ’24 when 0.81 million shares were sold. Director, Logos SPV 1 LP completed a deal on Aug 09 ’24 to buy 0.81 million shares. Meanwhile, Director Schmid John P. bought 17809.0 shares on Mar 25 ’24.
